发表论文

1. Wu J, Sakaguchi T, Takenaka K, Toyoda F, Tsuji K, Matsuura H, Horie M. A trafficking-deficient KCNQ1 mutation, T587M, causes a severe phenotype of long QT syndrome by interfering with intracellular hERG transport. J Cardio. 2018; (accepted) SCI收录,IF: 2.918

 

2. Wu J, Mizusawa Y, Ohno S, Ding WG, Higaki T, Wang Q, Kohjitani H, Makiyama T, Itoh H, Toyoda F, James AF, Hancox JC, Matsuura H, Horie M. A hERG mutation E1039X produced a synergistic lesion on IKs together with KCNQ1-R174C mutation in a LQTS family with three compound mutations. Sci Rep. 2018; 8(1): 3129. SCI收录,IF: 4.122

 

3. 宋苓苓,董超,翟晓晨,高洁,吴捷(通讯作者). 交感神经兴奋与1型长QT综合征(LQT1. 心脏杂志. 2018; 30(6): 728-730

 

4. Wu J, Ohno S, Ding WG, Chao D, LL Song, Matsuura H, Horie M. Who is the pathogenic culprit? A LQTS family with three compound genetic mutation. J Am Coll Cardiol. 2018; 72(16):C170.(29th Great Wall International Congress of Cardiology (GW-ICC))SCI收录

 

5. Hirose S, Makiyama T, Melgari D, Wu J, Yokoi F, Wuriyanghai Y, yamamoto Y, Kohjitani H, Nishiuchi S, Harita T, Hayano M, Yoshimoto J, Ohno S,

   Yoshida Y, Horie M, Kimura T.  Propranolol Inhibits Late Sodium Current in Long-QT Syndrome Type 3 Human Induced Pluripotent Stem Cell-drived

    Myocyte Model. Circulation. 2017; 136(Suppl 1): A15660. (Scientific Sessions of the American-Heart-Association / Resuscitation Science

    Symposium )SCI收录

 

6. Wu J(通讯作者), Ding WG, Horie M. Molecular pathogenesis of long QT syndrome type 1 (review).   J Arrhythm.

    2016; 32:381.

 

7. 翟晓晨吴捷(通讯作者).  三七总皂苷对脑缺血/再灌注损伤保护机制的研究进展中国药学杂志. 2016; 151: 24-27.

 

8. 董超,高洁,翟晓晨,吴捷(通讯作者). Kv1.5钾离子通道阻滞剂的研究进展. 中国药理学与毒理学杂志. 2016;30:1097-1101.

  

9. Wu J, Naiki N, Ding WG, Ohno S, Kato K, Zang WJ, Matsuura H, Horie  M. A Molecular Mechanism for Adrenergic-

    induced   Long QT Syndrome.  J Am Coll Cardiol. 2014; 63(8): 819. (IF:16.503)

 

10.Zhou J, Ding WG,Makiyama T, Miyamoto A, Matsumoto Y, Kimura H,  Tarutani Y, Zhao J, Wu J (通讯作者), Zang WJ,

    Matsuura H, Horie M.  A novel HCN4 mutation, G1097W, is associated with atrioventricular block. Circ J. 2014; 78(4): 938.

   (IF:3.96

 

11.Wu J, Ding W-G, Matsuura H, Tsuji K, Zang W-J, Horie M. Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor

     LY294002 on the human Kv1.5 channel. Br J Pharmacol. 2009; 156:377. (IF:5.20)

 

12.Wu J, W Shimizu, W-G Ding, Ohno S, Toyoda F, Itoh H, W-J Zang, Miyamoto Y, Kamakura S, Matsuura H, Nademanee K,

     Brugada J, Brugada P, Brugada R, Vatta M, Towbin JA, Antzelevitch C, Horie M.  KCNE2 Modulation of KV4.3 Current and

     its Potential Role in Fatal Rhythm Disorders. Heart Rhythm 2010; 7:199. (IF:5.05)

 

13.Wu J, Ding WG, Matsuura H, Horie M. Regulatory mechanisms underlying the modulation of GIRK1/GIRK4 heteromeric

    channels by P2Y receptors. Pflugers Arch. 2012; 464:625. (IF:4.87)

 

14.Nakajima T, Wu J (并列第一作者), Kaneko Y, Ashihara T, Ohno S, Irie T, Ding WG, Matsuura H, Kurabayashi M, Horie M. 

     KCNE3 T4A as the genetic basis of brugada-pattern electrocardiogram. Circ J. 2012; 76: 2763.  (IF:3.58)

 

15.Wu J, Ding WG,Zhao J,Zang WJ, Matsuura H,Horie M. Irbesartan mediated AT1 receptor blockade attenuates 

     hyposmostic-induced enhancement of IKs current and prevents shortening of action  potential duration in atrial myocytes.

     J  Renin Angiotensin Aldosterone Syst. 2014;15: 341-347   (IF:2.4).

 

16.Itoh H, Crotti L, Aiba T, Spazzolini C,Denjoy I, Fressart V, Hayashi K, Nakajima T, Ohno S, Makiyama T, Wu J,

   Hasegawa K,Mastantuono E, Dagradi F, Pedrazzini M, Yamagishi M, Berthet M,Murakami Y, Shimizu W, Guicheney P,

   Schwartz PJ, Horie M. The genetics underlying acquired long QT syndrome: impact for genetic screening.

   Eur Heart J. 2016; 37:1456-1464. (IF19.651)

  

17.Kato K, Makiyama Y, Wu J, Ding WG, Kimura H, Naiki N, et. al.Cardiac Channelopathies Associated with

   Infantile Fatal Ventricular Arrhythmias: From the Cradle to the Bench. J Cardiovasc Electrophysiol. 2014;25(1): 66. (IF:3.48)

 

18.Wang Q, Ohno S, Ding WG, Fukuyama M, Miyamoto A, Itoh H, Makiyama T, Wu J, et al. Phenotype variability in patients carrying KCNJ2 mutations. Cardiovasc Electrophysiol. 2014;25(5):522. (IF:3.48)

 

19.Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J,et al. Phenotype variability in patients carrying KCNJ2 mutations.Circ Cardiovasc Genet. 2012; 5: 344. (IF:6.73)

 

20.Li P, Ninomiya H, Kurata Y, Kato M, Miake J, Yamamoto Y, Igawa O,Nakai A, Higaki K, Toyoda F, Wu J, et al. Reciprocal control of hERG stability by Hsp70 and Hsc70 with implication for restoration of LQT2 mutant stability. Circ Res. 2011; 108: 458. (IF:11.86)

 

21.Itoh H, Oka Y, Ding WG, Sakaguchi T, Kimura H, Mizusawa Y, Miyamoto A, Wu J, Ohno S, Makiyama T, Ito M, Matsuura H, Horie M. Latent genetic backgrounds and molecular pathogenesis in acquired long QT syndrome with distinct arrhythmic triggers. Circulation. 2010; 122(Suppl 21): A10441.(Meeting Abstract)SCI收录

 

22.Gong YZ, Ding WG, Wu J, Tsuji K, Horie M, Matsuura H. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase. Eur J Pharmacol.

    2008; 600:18. (IF:2.79)

 

23.Lu J, Zhu SM, Zang WJ, Xu XL, Wu J, Horie M, et al. Protective mechanism of adenosine to the rat arterial endothelial dysfunction induced by hydrogen peroxide. Biol Pharm Bull. 2007; 30:1206. (IF:2.00)

 

24.Nagaoka I, Matsui K, Ueyama T, Kanemoto M, Wu J, Horie M, et al.A novel mutation of plakophilin-2 associated with arrhythmogenic right ventricular cardiomyopathy. Circ J. 2006; 70:933. (IF:3.58)